

What: Vaccine Committee Agenda
 Date & Time: April 17, 2025; 11:30 a.m. - 12:30 p.m. PT
 Location: Webinar/Teleconference – Individual Links Will be Sent to Each Attendee

Notice: The meeting may be recorded for the benefit of the minute-taker. The WVA intends to delete the recording after the minutes are approved.

Agenda

Approx. Time	Pg.		Topic/[Anticipated Action]	Presented by:
11:30 a.m.			1. Welcome & Introductions a. Notification of Recording	J. Zell
11:30 - 11:35 a.m.	Pg. 3-4	*	2. Consent Calendar Items a. Approve Vaccine Committee Minutes (November 7, 2025)	E. Marcuse
11:40 – 11:45 a.m.			3. Public Comment	Any
11:45 – 11:55 a.m.			4. DOH Immunization Program Updates a. RSV b. Influenza Vaccine Ordering c. COVID Vaccine Plan d. Vaccine Acceptance	J. Sherls
11:55 – 12:10 p.m.			5. WVA Updates a. Vaccine Assessment Loss (VAL) Task Force	J. Zell / P. Miller
12:10 – 12:20 p.m.			6. Revised Vaccine Committee Charter Discussion	E. Marcuse
12:20 - 12:30 p.m.			7. Challenging Times a. HHS: NIH, FDA, CDC b. WA State DOH: Budget constraints, leadership changes c. WCAAP Leadership Change d. WVA-DOH MOU renewal	E. Marcuse
12:30 p.m.			8. Closing	E. Marcuse

*Indicates additional materials / **Red text indicates an action item**

April 17, 2025

WVA Meeting of the Vaccine Committee

Proposed Form of Votes

The following are suggested forms of votes only. They are intended to be an aid to facilitate work by individual directors and committee members.

Items under Agenda Section 2:

VOTED: To approve November 7, 2024 meeting minutes.

[To approve November 7, 2024 meeting with the changes suggested at the meeting.]

**Meeting Minutes
Vaccine Committee Meeting
November 7, 2024; 11:30 a.m. – 12:30 p.m. PT**

I. Attendance. This meeting was conducted in-person and virtually. Participating in all or part of the meeting were the following individuals:

8 <u>Members</u>	26 <u>WVA</u>
9 Ed Marcuse, MD, Emeritus Professor of	27 Julia G. Zell, MA, Esq., Executive Director
10 Pediatrics, University of Washington, <i>Chair</i>	28 Cheri Cagle, Stakeholder Liaison
11 Amy Carter, MD, Allegro Pediatrics (virtual)	29
12 John Dunn, MD, MPH, Kaiser	30 <u>Helms & Company, Inc.</u>
13 Libby Page, MPH, King County Public Health	31 Patrick Miller, MPH, WVA, Administrative
14 (virtual)	32 Director
15 Jeff Gombosky, Pharmaceutical Research and	33 Ashley Ithal, MPH, Project Support Leader (virtual)
16 Manufacturers of America (virtual)	34
17 Carrie Jenner, MD, Pierce County Immunization	35 <u>Other</u>
18 Coalition (PCIC) (virtual)	36 Breelyn Young, GSK
19 Jamilia Sherls-Jones, DNP, MPH, Washington	37 Eric Jacobsen, GSK (virtual)
20 Department of Health	38 Lisa Templeton, Informed Choice WA (virtual)
21 Amy Person, MD, Benton-Franklin Health District	39
22 (virtual)	40
23 Kristi A. Rice, MD, Providence (virtual)	41
24 Sherri Zorn, MD, DOH & WVA Consultant	42

II. Summary of Actions Taken and/or Recommended

Actions Taken (votes adopted)

- i. To approve Vaccine Committee meeting minutes March 7, 2024.

III. Minutes

Welcome and Introductions

At 11:39 a.m. Dr. Marcuse called the meeting to order and announced that the meeting would be recorded for the benefit of the minute taker, to be deleted once the minutes are approved.

Calendar Consent Items

Dr. Marcuse asked for a motion to approve the minutes. Upon motion duly made and seconded, it was unanimously

- i. **VOTED: To approve Vaccine Committee meeting minutes March 7, 2024.**

Review of Prior Year Milestones

Ms. Zell reported on the year-long effort to finance pediatric RSV vaccines and bring over 34 birthing hospitals into compliance with WVA assessment requirements. She explained that while working with hospitals to create a dosage-based assessment (DBA) mechanism for in-hospital patients receiving state-supplied vaccines, the WVA Board also identified other provider types that have not been creating assessments, but are enrolled in the Washington State Childhood Vaccination Program (CVP). Provider onboarding efforts are ongoing and policy decisions about non-compliant providers will be discussed by the Board

HCA/WVA Billing Guidance

Ms. Zell noted that the Washington State Health Care Authority (HCA) updated their billing guidance this year, which has caused some confusion amongst providers in relation to WVA's DBA submission guidance. Ms. Cagle wrote a synopsis of these changes that was previously distributed to the Committee and sent to providers requesting additional aid

Office Experiences & Challenges

73 Dr. Carter commended the Washington Department of Health (DOH) for improvements in the CVP process;
74 however, she noted that vaccine supply timeliness remains an issue. She explained her practice's challenges and
75 made suggestions for improvement. Dr. Rice stated there were oversupply issues in previous years, and constraints
76 this year. Dr. Jenner reported concerns with being unable to order entire vaccine supply at one time and that
77 staggered delivery was challenging for her Vaccine Coordinator. Discussion ensued.
78

79 The issue of recent shipment issues related to McKesson's depot was raised. Ms. Sherls reported that the DOH is
80 working with their Centers for Disease Control and Prevention (CDC) Project Officer to attempt to prevent future
81 issues. Ms. Sherls gave an update on the DOH vaccine allocation process and status by vaccine type. She concluded
82 with an update on RSV vaccine administration numbers from the DOH immunization dashboard.
83

84 WVA Update on Immediate Challenges

85 86 *Rebuilding Cash Reserves*

87 Ms. Zell reviewed the CY2023 and CY2024 cumulative impacts on cash reserves including pre-funding 2023 RSV
88 vaccines, pre-funding Fall 2024 influenza, COVID, and RSV vaccines, and the amount recouped. Ms. Zell and Mr.
89 Miller highlighted WVA's plans to rebuild reserves in the next few years.
90

91 *Renewing DOH WVA MOU*

92 Dr. Marcuse reported that the WVA is working with the DOH on renewing the DOH-WVA Memorandum of
93 Understanding around certain fees paid to support vaccine distribution costs that is set to expire at the end of 2024.
94

95 *Addressing Cybersecurity*

96 Ms. Zell reported that the WVA recently conducted a security risk assessment (SRA) with Stoel Rives LLP. There
97 were some findings that the WVA addressed immediately, and others that will take more time to mitigate and are less
98 time sensitive. The WVA will conduct future SRAs annually.
99

100 WVA Vaccine Committee Charter Discussion

101 Dr. Marcuse reviewed the current version of the WVA Vaccine Committee Charter while providing the history behind
102 why the original charter was created. He requested feedback on potential changes and activities the Committee could
103 undertake.
104

105 **IV. Public Comments – none.**

106
107 **V. Closing**

108
109 The meeting adjourned at 12:28 p.m. PT.